drugset / Trial / NCT00376103

Radiation Boost for Newly Diagnosed Glioblastoma Multiforme

NCT00376103

Phase 1/2 Terminated 3 enrolled Methodist Healthcare - Memphis
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine treatment related toxicity, tumor response, progression-free survival and quality of life of newly diagnosed Glioblastoma Multiforme (GBM) patients undergoing a combination of surgical resection, brachytherapy and external beam radiation with concomitant temozolomide, followed by adjuvant temozolomide.

Timeline

Start
2006-08
Primary completion
2008-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule 75 mg/m2
Subject Temozolomide Small molecule 150 mg/m2
Subject Temozolomide Small molecule 200 mg/m2

Indications